Piper Jaffray Companies initiated coverage on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research note published on Tuesday. The firm issued an overweight rating and a $200.00 price target on the stock.
A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a hold rating to a buy rating and set a $184.00 price target for the company in a report on Tuesday, October 24th. Stifel Nicolaus reissued a buy rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. BidaskClub cut shares of IDEXX Laboratories from a hold rating to a sell rating in a research note on Saturday, December 16th. Canaccord Genuity reissued a buy rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research note on Friday, October 6th. Finally, Aegis reissued a sell rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $177.43.
Shares of IDEXX Laboratories (NASDAQ:IDXX) traded up $3.26 on Tuesday, hitting $179.36. 548,140 shares of the stock were exchanged, compared to its average volume of 511,164. The company has a debt-to-equity ratio of -12.48, a current ratio of 0.95 and a quick ratio of 0.77. The stock has a market cap of $15,640.00, a P/E ratio of 58.23, a PEG ratio of 2.34 and a beta of 0.42. IDEXX Laboratories has a 1-year low of $116.54 and a 1-year high of $180.20.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 EPS. equities analysts forecast that IDEXX Laboratories will post 3.24 EPS for the current fiscal year.
In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan W. Ayers sold 2,160 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the sale, the chief executive officer now directly owns 1,077,112 shares in the company, valued at $179,910,017.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 130,160 shares of company stock worth $20,019,685. 2.77% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. D.A. Davidson & CO. boosted its stake in shares of IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after purchasing an additional 385 shares during the last quarter. Sun Life Financial INC boosted its stake in shares of IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after purchasing an additional 636 shares during the last quarter. BB&T Investment Services Inc. acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $104,000. Zions Bancorporation acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $162,000. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of IDEXX Laboratories by 1,000.0% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after purchasing an additional 1,000 shares during the last quarter. 86.66% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2018/01/17/idexx-laboratories-idxx-receives-new-coverage-from-analysts-at-piper-jaffray-companies.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.